Barcelona, Spain – 27 Aug 2022. In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by artificial intelligence (AI) is superior to initial sonographer assessment, according to late breaking research presented in a Hot Line session at ESC Congress 2022. Dr. David Ouyang of the Smidt Heart Institute at Cedars-Sinai, Los Angeles, US said: “There has been much excitement about the use of AI in medicine, but the technologies are rarely assessed in prospective clinical trials.
We previously developed one of the first AI technologies to assess cardiac function (left ventricular ejection fraction; LVEF) in echocardiograms and in this blinded, randomised trial, we compared it head to head with sonographer tracings. This trial was powered to show non-inferiority of the AI compared to sonographer tracings, and so we were pleasantly surprised when the results actually showed superiority with respect to the pre-specified outcomes.”
Accurate assessment of LVEF is essential for diagnosing cardiovascular disease and making treatment decisions. Human assessment is often based on a small number of cardiac cycles that can result in high interobserver variability. EchoNet-Dynamic is a deep learning algorithm that was trained on echocardiogram videos to assess cardiac function and was previously shown to assess LVEF with a mean absolute error of 4.1–6.0% .2 The algorithm uses....READ MORE
Earlier this year, Samsung established the era of mobile AI with the launch of the Galaxy S24 series and committed to introducing Galaxy AI1 to a wider range of devices....
From the high tech to the medical sector, AI is showing all its resources, opening the doors to many global innovations. In a rapidly changing world, modern society is...
Barcelona, Spain – 27 Aug 2022. In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by artificial intelligence (AI) is superio...
A virtual marketplace leading your business into the future
